Phase II Neoadjuvant Study of EC followed by Abraxane in opetable breast cancer.
Phase 2
- Conditions
- breast cancer
- Registration Number
- JPRN-UMIN000014351
- Lead Sponsor
- Kawasaki Medical School
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 25
Inclusion Criteria
Not provided
Exclusion Criteria
1)cardiac dysfunction 2)severe complication(uncontoroled DM, hypertension, renal failure, hepatic failure, severe infection, mental disorder) 3)pregnancy, lactation 4)double cancer 5)bilateral breast cancer 6)pulmonary fibrosis, interstitial pneumonia 7)allergy 8)neuropathy 9)HBs antigen positive
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method pathological complete response (pCR)
- Secondary Outcome Measures
Name Time Method